A study of TAK-279 for Crohn's disease
Part of Digestive system clinical trials.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old (19 or older in South Korea).
- You have been diagnosed with Crohn's disease for at least 30 days and it is moderately to severely active.
- You have tried at least one earlier treatment (like a biologic or other advanced therapy) that didn't work or caused side effects.
- You do not have a current ostomy or other types of colitis (like ulcerative colitis).
- You have not already failed 3 or more different types of advanced therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This study is for people who already completed 52 weeks of treatment with TAK-279 for ulcerative colitis or Crohn's disease and saw improvement. It gives them the option to continue the medication long-term to see if the benefits last.
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.